Kiora Pharmaceuticals, Inc. KPRX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -16.80% | -24.03% | |||
| Gross Profit | 16.80% | 24.03% | |||
| SG&A Expenses | -14.19% | 10.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.12% | -4.84% | |||
| Operating Income | 15.12% | 4.84% | |||
| Income Before Tax | 14.02% | 66.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.02% | 62.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.02% | 62.89% | |||
| EBIT | 15.12% | 4.84% | |||
| EBITDA | 15.19% | 4.87% | |||
| EPS Basic | 26.86% | 70.56% | |||
| Normalized Basic EPS | 29.79% | 23.07% | |||
| EPS Diluted | 26.10% | 70.56% | |||
| Normalized Diluted EPS | 29.79% | 23.07% | |||
| Average Basic Shares Outstanding | 17.56% | 26.02% | |||
| Average Diluted Shares Outstanding | 17.56% | 26.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||